Doxall™ in the Lab

Doxall™ skin and surface products represent a major scientific advance in sanitising and cleaning disinfection technology. Doxall™ comes from medical research into harmful drug resistant microorganisms. Our patented science has been rigorously tested and verified in independent laboratories and 6 Universities. This includes:

  • National Institute of Allergy and Infectious Diseases (NIH, USA)
  • Eurofins BioPharma (AU)
  • Microchem Laboratory (USA)
  • Defence Science and Technology Group
    Department of Defence, Australian Government
  • IBT Bioservices (USA)
  • University of New South Wales
  • Murdoch University
  • RMIT University
  • La Trobe University
  • University of California (Riverside) 
  • State University of Louisiana
  • Public Health England



The proprietary patented fatty acid compound used in DoxallTM products has been successfully tested against the following pathogens:


  • Herpes simplex virus-1
  • Herpes simplex virus-2
  • Murine hepatitis virus-1 (COVID-19 surrogate)
  • Ebola
  • Influenza
  • Rhinovirus
US Centre for Disease Control Biggest Threats List (Bacteria)
  • Methicillin-resistant Staphylococcus aureus (MRSA)
  • Streptococcus pneumoniae
  • C. difficile (vegetative cells and spores)
  • Carbapenem-resistant Enterobacteriaceae (CRE)
  • Acinetobacter baumannii
  • Extended spectrum beta-lactamase producing Enterobacteriaceae (ESBLs)
  • Multidrug-resistant Pseudomonas aeruginosa

        Other bacteria

        • E. Coli
        • Staphylococcus aureus
        • Streptococcus pyogenes
        • E. coli (including MCR-1 positive)
        • Klebsiella pneumoniae
        • Proteus vulgaris

                  Biowarfare agents

                  • Anthrax (B. atrophaeus* and B. anthracis (Sterne))
                  • Botulism (C. butyricum)
                  • Pseudomallei (B. thailandensis)


                      • Candida auris
                      • Candida albicans